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Abstract: Central auditory processing disorder (CAPD) is associated with difficulties hearing and
processing acoustic information, as well as subsequent impacts on the development of higher-order
cognitive processes (i.e., attention and language). Yet CAPD also lacks clear and consistent diagnostic
criteria, with widespread clinical disagreement on this matter. As such, identification of biological
markers for CAPD would be useful. A recent genome association study identified a potential
CAPD risk gene, USH2A. In a homozygous state, this gene is associated with Usher syndrome type
2 (USH2), a recessive disorder resulting in bilateral, high-frequency hearing loss due to atypical
cochlear hair cell development. However, children with heterozygous USH2A mutations have
also been found to show unexpected low-frequency hearing loss and reduced early vocabulary,
contradicting assumptions that the heterozygous (carrier) state is “phenotype free”. Parallel evidence
has confirmed that heterozygous Ush2a mutations in a transgenic mouse model also cause low-
frequency hearing loss (Perrino et al., 2020). Importantly, these auditory processing anomalies were
still evident after covariance for hearing loss, suggesting a CAPD profile. Since usherin anomalies
occur in the peripheral cochlea and not central auditory structures, these findings point to upstream
developmental feedback effects of peripheral sensory loss on high-level processing characteristic
of CAPD. In this study, we aimed to expand upon the mouse behavioral battery used in Perrino
et al. (2020) by evaluating central auditory brain structures, including the superior olivary complex
(SOC) and medial geniculate nucleus (MGN), in heterozygous and homozygous Ush2a mice. We
found that heterozygous Ush2a mice had significantly larger SOC volumes while homozygous Ush2a
had significantly smaller SOC volumes. Heterozygous mutations did not affect the MGN; however,
homozygous Ush2a mutations resulted in a significant shift towards more smaller neurons. These
findings suggest that alterations in cochlear development due to USH2A variation can secondarily
impact the development of brain regions important for auditory processing ability.
Keywords: central auditory processing disorder; Usher syndrome type 2; USH2A; superior olivary
complex; medial geniculate nucleus
1. Introduction
Individuals diagnosed with central auditory processing disorder (CAPD) experience
difficulties with multiple mechanisms that subserve acoustic information processing. These
include, but are not limited to, sound localization, temporal discrimination, discrimination
between two or more competing auditory stimuli, auditory pattern recognition and dichotic
listening [1,2]. Moreover, affected individuals have difficulties with speech processing
that include attending to verbal input (i.e., oral instruction) and comprehending complex
sentences [3]. As a result, affected children often experience poor academic performance
and reduced quality of life [4,5].
Nonetheless, there is ongoing debate within the audiology community as to the def-
inition of—and diagnostic criteria for—CAPD. This includes whether CAPD should be
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considered a DSM-defined disorder. According to the American Speech and Hearing
Association (ASHA), individuals clinically diagnosed with any of the aforementioned audi-
tory impairments have clinically defined CAPD [1]. However, multiple other audiology
groups (i.e., the American Academy of Audiology (2010) [6], the British Society of Audiol-
ogy (2011) [4] and the Canadian Interorganizational Steering Group for Speech-Language
Pathology and Audiology (2012) [7]) adopt different standards. The discrepancies across
organizations include differences in phenotypic description, ascribed causal mechanisms
and classification of co-morbidities (see [2] for a review). These disparities contribute to
controversy in recognizing CAPD, with varied results in the attribution of symptoms to
other disorders. For instance, Dawes and Bishop (2010) [8] reported that 52% of children di-
agnosed with CAPD could also fit a diagnosis of dyslexia, specific language impairment, or
both. Children with CAPD have also been shown to meet behavioral profiles for attention
deficit disorder [9,10], suggesting CAPD may resemble a more general cognitive disorder
rather than an auditory perception disorder.
The lack of a clear causal genetic, peripheral or neurologic mechanism adds another
layer of difficulty to defining CAPD. Ongoing research is crucial to determining whether
CAPD is the result of poor auditory processing and/or integration with higher-order
cognitive processes, subclinical hearing impairments that affect cochlear development,
comorbid cognitive disorders (as discussed above), or a combination of factors. Addition-
ally, genetic contributions to CAPD remain understudied [11]. Brewer et al. (2016) [12]
reported that auditory processing skills (i.e., temporal processing and pitch discrimination)
subserving the perception of spoken language are heritable. As such, it is possible that
auditory processing difficulties seen in individuals with CAPD arise from genetic variants
and/or mutations.
One promising CAPD-risk gene is USH2A, which is clinically associated with Usher
syndrome type 2 (USH2; [13]). Individuals with USH2 experience bilateral hearing loss
at high frequencies and retinitis pigmentosa beginning at puberty [14,15]. USH2 results
from homozygous loss-of-function of USH2A, with heterozygous individuals considered
to be unaffected carriers [16,17]. The USH2A protein is expressed primarily in the cochlea
and retina but not in the brain, meaning that USH2 is considered a peripheral disorder [18].
Usherin plays a critical role in cochlear hair cell maturation and acts to connect developing
stereocilia with kinocilium via a transient lateral ankle link that helps guide developing
hair cells into their proper orientation [19,20]. Lui et al. (2007) [19] reported that the outer
hair cells of the basal cochlea were missing in mice with a homozygous knockout of Ush2a
(the rodent homolog of USH2A), consistent with high-frequency hearing loss in individuals
with USH2.
While it is well established that homozygous mutations of USH2A cause UHS2, little
is known about how heterozygous mutations affect hearing ability or auditory processing.
Historically, heterozygous mutations of USH2A have been considered nonpathogenic, with
such individuals classified as “unaffected carriers” of USH2. Yet several studies report low-
frequency hearing loss or sensorineural abnormalities in USH2 carriers [20–23]. As a result
of abnormalities reported in USH2 carriers, researchers have recently become interested in
how heterozygous mutations of USH2A might contribute to auditory processing ability,
including disorders like CAPD.
To study the relationship between heterozygous USH2A mutations, CAPD and lan-
guage outcomes, Perrino et al. (2020) [24] sought to combine human whole genome se-
quencing with mouse model behavioral phenotyping. Specifically, we conducted genome
sequencing of a family with individuals affected by a severe expressive language disorder,
as well as phenotypic characteristics of CAPD (i.e., difficulties understanding oral instruc-
tions). Affected family members were found to have a heterozygous stop-gain mutation
in the USH2A gene (NP_996816:p.Gln4541*), suggesting that the heterozygous USH2A
mutation might have caused the auditory processing deficits in affected family members.
To further test this hypothesis, we evaluated Ush2a heterozygous (HT) mice on a battery of
rapid auditory processing tasks. We found that HT mice had low-frequency hearing im-
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pairments, which subsequently contributed to higher-order auditory processing difficulties
that persisted even when hearing deficits were covaried out. Importantly, simultaneous
testing showed that Ush2a KO mice were affected by significant high-frequency auditory
processing impairments, a defining characteristic of USH2. These low-level hearing deficits
in homozygous mice also contributed to higher-order auditory processing difficulties reflec-
tive of central mechanisms. Human genome-wide association studies (GWAS) also suggest
that heterozygous USH2A mutations contribute to a CAPD phenotype. Specifically, though
the same stop-gain mutation that was reported in our discovery family was not present in
the UK10K dataset [25], children with pathogenic heterozygous USH2A variants nonethe-
less showed low-frequency hearing impairments (i.e., increased low-frequency hearing
thresholds (+1.2 dB HL at 500 Hz)), as well as reductions in vocabulary, when compared to
children without an USH2A mutation [24]. These results were highly novel in identifying
heterozygous USH2A mutations as a CAPD risk, with impacts on low-frequency hearing
as well as higher-order auditory processing abilities necessary for typical language and
communication development.
This current study builds upon Perrino et al. (2020) [24]. Here, using postmortem brains
from the behaviorally evaluated mice, we analyzed the neuroanatomical consequences
of Ush2a genetic variations. We hypothesized that, despite the lack of Ush2a expression
in the CNS, anatomical anomalies may be evident in the overall volume, neuron size
and/or neuronal population in brain structures that subserve central auditory processing
(i.e., the medial geniculate nucleus (MGN) and superior olivary complex (SOC)) in both
heterozygous and knockout subjects. We predicted differing anatomical anomalies between
heterozygous (HT) and homozygous (KO) subjects, given that HT mutations affect low-
frequency processing and KO mutations affect high-frequency processing. Results from
volumetric analysis showed a significant increase in right SOC volume for Ush2a HT mice,
coupled with a significant decrease in right SOC volume for Ush2a KO mice. Within
the right MGN, we found a significant shift towards more smaller neurons in Ush2a KO
mice, while HT mice were unaffected. Together, our results suggest that altered cochlear
development impacts higher-order auditory processing at both a functional and structural
level, but differently so in Ush2a HT and KO subjects. These anomalies could account for
complex auditory and speech processing impairments observed in some individuals with
CAPD, as well as those with Usher syndrome type 2.
2. Materials and Methods
2.1. Subject Generation
Six homozygous Ush2a male subjects (F1 generation) were rederived on an 129S4/SvJaeJ
background strain at the Center for Mouse Genome Modification (previously known as the
Gene Targeting and Transgenic Facility) at UConn Health via genetic material obtained from
Dr. Jun Yang (University of Utah; [19]). These six male Ush2a KO mice were crossed with six
wildtype (WT) control mice (29S4/SvJaeJ; stock number 009104) obtained from the Jackson
Laboratory (Bar Harbor, ME) to generate an all heterozygous (HT) F2 generation. To generate
experimental (F3) subjects, HT ×HT breeding pairs from the F2 generation were established,
resulting in litters containing all three genotypes (homozygous, heterozygous and wildtype).
Following weaning (postnatal day (P) 21), ear punches were collected from each subject and
used for genotyping via PCR (DNA primer information can be found in [19]). After puberty
(P40), subjects from the F3 generation were randomly selected and used for behavioral testing
and histological assessment. Additionally, at this time, experimental subjects were single
housed in standard Plexiglass mouse chambers (12 h/12 h light–dark cycle) with food and
water available ad libitum. The subjects used here, as well as the breeding information, are the
same as used in Perrino et al. (2020) [24].
2.2. Behavioral Testing
Beginning at P65, subjects were assessed on a battery of auditory processing tasks
aimed to evaluate the subject’s ability to process and discriminate complex acoustic infor-
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mation relevant to communication ability (see [26] for review). For a complete description
of the behavioral battery each subject underwent, see [24]. In short, acoustic processing
ability was assessed using a modified prepulse inhibition (PPI) paradigm in which the
subject’s acoustic startle response was measured following the presentation of a loud
(105 dB, 50 ms) startle eliciting stimulus (SES; 1000–10,000 Hz broadband burst) (“uncued”
trials). During each testing session, acoustic cues were pseudorandomly presented before
the SES—the subject’s acoustic startle response during “cued” trials was measured. If the
subject was able to detect the acoustic cue—the goal of each auditory processing task—their
acoustic startle response should have been reduced (or attenuated) as the cue informs the
subject that the SES is about to occur. The difference in startle response during “uncued”
and “cued” trials can be calculated as an “attenuation score”—a ratio of [average “cued”
startle response/average “uncued” startle response] × 100. The lower the attenuation
score, the better the subject’s performance in detecting the cue. Subjects with an attenuation
score of 100% were deemed to have not detected the cue, as their “uncued” and “cued”
startle responses were similar.
Each subject underwent a variety of acoustic processing tasks, each designed to assess
a different aspect of acoustic processing ability. Subjects were first evaluated on a normal
single tone (NST) task that used a simple pure tone cue to assess baseline hearing ability,
typical acoustic startle response (i.e., motor ability), and prepulse inhibition. Attenuation
scores for the NST task were used as a covariate for subsequent auditory processing tasks
to eliminate individual differences. More complex auditory processing tasks were used to
evaluate spectral, temporal, or both spectral and temporal (spectro-temporal) aspects of
auditory processing ability. For example, embedded tone (EBT) consisted of a pure tone
background and an auditory cue that was different than the pure tone background and
varied in duration. Pitch discrimination (PD) consisted of a pure tone background and an
acoustic cue that had a fixed duration but varied in frequency. Additionally, each task was
presented in both a sub-ultrasonic and an ultrasonic frequency range. The use of multiple
auditory processing tasks, combined with the use of multiple frequency ranges, allows
for the detailed evaluation of how USH2A mutations affect different aspects of acoustic
processing ability. See [24] for a description of each task used.
2.3. Histology
Following the completion of behavioral testing (P150) and after being weighed, sub-
jects were anesthetized using ketamine (100 mg/kg) and xylazine (15 mg/kg) and tran-
scardially perfused using a 0.9% saline solution followed by 10% formalin. The brains
were postfixed in 10% formalin following extraction. Each brain was serially and coronally
sectioned (60 µm) using a Leica VT1000 S vibratome (Leica Biosystems Inc., Buffalo Grove,
IL, USA). Olfactory bulbs were removed using a surgical blade and the flat surface that re-
mained was glued to the vibratome stage—slicing began at the cerebellum and progressed
towards the frontal cortex (posterior→ anterior). Every coronal section of the brain was
mounted to a gelatin-subbed glass slide until the cerebellum was completely sectioned.
This methodology was performed to ensure the complete sectioning of the superior olivary
complex. Sectioning continued past the cerebellum and every second section was mounted
on a gelatin-subbed glass slide. All slides were subjected to cresyl violet to stain for Nissl
bodies. Slides were then cover-slipped with DPX mounting medium.
2.4. Stereological Measurements
Brain tissue underwent stereological analysis via Stereo Investigator (MBF Biosciences,
Williston, VT, USA) using a Zeiss Axio Imager A2 microscope (Carl Zeiss, Thornwood, NY,
USA). Superior olivary complex (Figure 1A) and medial geniculate nucleus (Figure 1B)
volumes were estimated using the Cavalieri Estimator probe, neuron population was esti-
mated using the Optical Fractionator probe (Figure 1C), and the Nucleator probe was used
to measure neuronal cell area (Figure 1D). Measurements within the SOC were performed
at a sampling frequency of every section (across eight total sections), while measurements
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within the MGN were performed with a sampling frequency of every second section (across
six total sections). Contours to define each region and to provide volumetric estimates
were determined via stereotaxic atlas [27] and drawn at 2.5× magnification. All other
stereological measurements (i.e., neuron population and neural cell area) were evaluated
at 100×magnification. A sampling grid of 150 µm × 150 µm and a 30 µm × 30 µm count-
ing frame was selected for the SOC, while a sampling grid of 225 µm × 225 µm and a
25 µm × 25 µm counting frame was selected for the MGN. Neurons were defined as having
one distinct nucleolus within the nucleus—glial cells or other cell types within the brain
were not counted (Figure 1C).
Genes 2021, 12, x FOR PEER REVIEW 5 of 12 
 
 
2.4. Stereological Measurements 
Brain tissue underwent stereological analysis via Stereo Investigator (MBF 
Biosciences, Williston, VT, USA) using a Zeiss Axio Imager A2 microscope (Carl Zeiss, 
Thornwood, NY, USA). Superior olivary complex (Figure 1A) and medial geniculate 
nucleus (Figure 1B) volumes were estimated using the Cavalieri Estimator probe, neuron 
population was estimated using the Optical Fractionator probe (Figure 1C), and the 
Nucleator probe was used to measure neuronal cell area (Figure 1D). Measurements 
within the SOC were performed at a sampling frequency of every section (across eight 
total sections), w le measurem nts within the MGN were performed with a sampling 
frequency of every second section (across six total se tions). Co tours t  define each 
region and to provide volumetric estimates were determined via stereotaxic atlas [27] and 
drawn at 2.5× magnification. All other stereol gical measureme ts (i.e., neuron 
population and neural cell area) were evaluated at 100× magnification. A sampling grid 
of 150 µm × 150 µm nd a 30 µm × 30 µm counting frame was selected for the SOC, while 
a sampling grid of 225 µm × 225 µm and a 25 µm × 25 µm counting frame was selected for 
the MGN. Neurons were defined as having one distinct nucleolus within the nucleus—
glial cells or other cell types within the brain were not counted (Figure 1C). 
 
Figure 1. Stereological Measurements. Visual representation of the superior olivary complex 
(SOC) (A) and medial geniculate nucleus (MGN) (B) taken at 2.5× magnification to determine 
volume of brain region. (C) The Optical Fractionator probe of Stereo Investigator was used to 
determine neuron population. Arrow 1 indicates a neuron that was counted due to the presence of 
a clearly defined nucleolus, while Arrow 2 indicates a cell that was not counted. (D) The Nucleator 
probe was used to determine neuron size (area). Optical Fractionator and Nucleator probes were 
used at 100× magnification. 
2.5. Statistical Analysis 
Genotype differences for the volume of each region (i.e., SOC and MGN), neuron 
population within each region, and average neuronal cell area within each region, were 
Figure 1. Stereological Measurements. Visual representation of the superior olivary complex (SOC) (A) and medial
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2.5. Statistical Analysis
Genotype differences for the volume of each region (i.e., SOC and MGN), neuron
population within each region, and average neuronal cell area within each region, were
analyzed using univariate ANOVAs. Additionally, univariate ANOVAs were performed
between each Genotype to determine how heterozygous Ush2a mutations differed from
homozygous mutations—a necessary analysis for determining how each mutation con-
tributes to the behavioral differences between HT and KO subjects (low-frequency vs.
high-frequency auditory processing). To evaluate how Ush2a mutations affect neuronal
cell size (area) distribution, the Kolmogorov–Smirnov (K–S) test was conducted on the
cumulative percent distribution for each Genotype. Analyses were conducted for the
left and right hemispheres, as well as both together (i.e., total SOC or total MGN). All
univariate ANOVAs and correlational analyses were conducted via the car package [28] in
R (v3.4.4; [29]). A total of 21 subjects were used in the histological assessment of the SOC
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(WT, n = 7 (one subject dropped due to poor tissue integrity); HT, n = 7; KO, n = 7) and
22 subjects for the histological assessment of the MGN (WT, n = 8; HT, n = 7; KO, n = 7).
2.6. Ethics
All animal procedures were approved by the University of Connecticut’s Institute for
Animal Care and Use Committee (IACUC; Protocol No. A18-050) and followed the Guide
for the Care and Use of Laboratory Animals [30]. This study was designed to comply with
ARRIVE guidelines [31].
3. Results
3.1. SOC Volumetric Analysis
A univariate ANOVA comparing SOC volume revealed a main effect of Genotype
in the right SOC [right: F(2, 18) = 4.034, p < 0.05], reflecting a volumetric increase in
HT subjects relative to WTs, coupled with a volumetric decrease in KO subjects (HT vs.
KO; F(1, 12) = 9.558, p < 0.05).There was no significant Genotype effect in the left SOC
[F(2, 18) = 0.568, p > 0.05], nor for the total SOC [F(2, 18) = 1.874, p > 0.05] (Figure 2A).
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Ush2a mutations increased the volume of the right SOC while homozygous Ush2a mutations reduced the volume of the right
SOC. (B,C) There were no significant genotype differences in neuron population (B) or average neuron area (C). * p < 0.05.
3.2. MGN Volumetric Analysis
A univariate ANOVA comparing MGN volume revealed no main effect of genotype
in either hemisphere (left: F(2, 19) = 0.468, p > 0.05; right: F(2, 19) = 0.0598, p > 0.05; total:
F(2, 19) = 0.232, p > 0.05) (Figure 3A).
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Figure 3. Histological a sessment in MGN. (A–C) There were no significant genotype differences when valuating volume
(A), neuron population (B) or neuron area (C). (D) Comparison of cumulative percent distribution of neuronal cell size (area)
revealed a significant shift towards fewer larger neurons and more smaller neurons in the right MGN in Ush2a homozygous
(KO) mice.
3.3. SOC Cellular Analysis
There was no significant Genotype effect when evaluating neuron population within
the SOC (left SOC: F(2, 18) = 0.183, p > 0.05; right SOC: F(2, 18) = 0.040, p > 0.05; to-
tal SOC: F(2, 18) = 0.028, p > 0.05) (Figure 2B). Additionally, there was no Genotype
effect on average neuron size (area) in the SOC (left SOC: F(2, 18) = 2.3048, p > 0.05;
right SOC: F(2, 18) = 0.290, p > 0.05; total SOC: F(2, 18) = 0.437, p > 0.05) (Figure 2C).
3.4. MGN Cellular Analysis
There was no significant Genotype effect on neuron population within the MGN (left MGN:
F(2, 19) = 0.174, p > 0.05; right MGN: F(2, 19) = 0.174, p > 0.05; total MGN: F(2, 19) = 0.168, p > 0.05)
(Figure 3B), nor for average neuron size (area) within the MGN (left MGN: F(2, 19) = 0.219, p > 0.05;
right MGN: F(2, 19) = 1.039, p > 0.05; total MGN: F(2, 19) = 0.965, p > 0.05) (Figure 3C). Addition-
ally, in the left MGN, no significant K–S statistics for the cumulative distribution of cell size were
seen (left MGN (WT vs. HT): p > 0.05; left MGN (WT vs. KO): p > 0.05; left MGN (HT vs. KO): p
> 0.05). However, within the right MGN, WT and KO subjects w re significantly different (right
MGN (WT vs. KO): p < 0.05), with a shift towards more maller neurons in KO subjects. WT vs.
HT subjects did not yield a significant K–S stati tic (right MGN (WT vs. HT): p > 0.05), nor did
HT v . KO subjects (right MGN ( vs. KO): p > 0.05) (Figure 3D). No effects were seen for the
overall MGN (total MGN (WT vs. HT): p > 0.05; total MGN (WT s. KO): p > 0.05; total MGN
(HT vs. KO): p > 0.05).
4. Discussion
The current study was designed to neuroanatomically evaluate the central auditory
consequences of heterozygous and homozygous mutations in an Ush2a mouse model. The
study was based on human clinical evidence that homozygous mutations of USH2A result
in Usher syndrome type 2 [13], as well as recent evidence that heterozygous USH2A muta-
tions may be a genetic risk factor for CAPD [24]. Since anomalies in auditory processing
represent core features of both CAPD and USH2 (though with very different functional
profiles; [3,14]), central auditory structures of the superior olivary complex and medial
geniculate nucleus were evaluated. Results showed that heterozygous Ush2a mutations
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resulted in an increase in right SOC volume, while homozygous Ush2a mutations resulted
in a decrease in right SOC volume, as well as a shift towards fewer large and more small
neurons in the right MGN. To the best of our knowledge, these results are the first to report
neuroanatomical anomalies in a mouse model of either CAPD or Usher syndrome type
2. The results are particularly exciting given a lack of usherin expression in the brain [18],
which suggests substantial developmental effects of peripheral auditory anomalies on the
central auditory system.
Neuroanatomical Differences between HT and KO Subjects
The two structures evaluated in this study, SOC and MGN, both play an important
role in the central auditory system (see [32] for review). The SOC is one of the first
stops for ascending auditory information, primarily mediating sound localization via the
convergence of binaural sensory input [33,34]. To our knowledge, there are not significant
processing differences between right and left SOC, both of which receive input from
ipsilateral and contralateral cochlea [35]. Here, we report that the right SOC is smaller
in KO subjects, and larger in HT subjects. In considering possible mechanisms for these
anomalies, Liu et al. (2007) [19] reported that mice with a homozygous Ush2a deletion had
an absence of outer hair cells in the basal cochlea, an area primarily responsible for the
detection of high-frequency auditory information. This cochlear abnormality could have
contributed to the observed reductions in right SOC volume, since regions that respond
to high-frequency auditory information are presumably receiving anomalous/degraded
sensory input. The notion that anomalous brain development may result from altered
or absent sensory input is well established and has been studied in multiple sensory
modalities, including the auditory system [36–41]. These SOC reductions in KO subjects
may have further contributed to the high-frequency processing impairments reported
by Perrino et al. (2020) [24]. The increase in SOC volume in subjects with heterozygous
Ush2a mutations was surprising. However, there is ample evidence that atypical structural
increases in the CNS can cause functional impairments (e.g., macrocephaly). Future
studies are needed to (1) evaluate cochlear development and organization in heterozygous
Ush2a mutant mice, and (2) determine how non-neuronal cell types (i.e., glial cells) might
contribute to the volumetric differences reported here. It is possible that changes in glial
morphology within the SOC in HT and/or KO mice contributed to the observed behavioral
phenotypes. Nonetheless, the increase in right SOC volume in HT subjects provides
evidence that altered sensory input can impact CNS development, as well as evidence that
underlying neurologic anomalies may exist in CAPD.
In addition to the SOC, we assessed the MGN, a thalamic nucleus responsible for
auditory processing. The MGN has been shown to be affected in other language- and
communication-neurodevelopmental disorders; for example, Galaburda et al. (1994) [42]
reported a shift towards more smaller MGN neurons in the brains of individuals with
dyslexia. These initial findings of atypical MGN morphology led to further studies with
animal models using induced mutations of dyslexia-risk genes and induced neuronal
migration abnormalities. Both models showed anomalous MGN anatomy [43–45]. Im-
portantly, atypical MGN development has been shown to impact auditory processing
ability [46–48], which is a fundamental skill necessary for language development, as well
as a good predictor of later language outcomes [49]. Within the autism spectrum disorders
(ASD) population, for example, reductions in MGN volume [50] and altered thalamocorti-
cal connectivity [51] have been reported, and similar MGN anomalies have been observed
in genetic mouse models of ASD [52], a disorder frequently characterized by anomalous
language development and language impairments. Our findings that homozygous Ush2a
mutations shift the cell size distribution towards fewer large and more small neurons in
the right MGN further substantiate the potential role of MGN in language functions [53].
Finally, it is important to note that effects were observed explicitly in the right SOC
and right MGN in both HT and KO mice. Given overwhelming evidence of left hemisphere
lateralization for language and underlying auditory temporal processing [54–56], these
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results may seem puzzling. However, it is important to note that recent mouse research
has shown evidence of left hemisphere lateralization in A1 specifically for processing of
ultrasonic vocalizations and other spectro-temporal acoustic information, while right A1
may play a stronger role in frequency-based processing [57]. Although lateralization of
MGN was not observed in this study, it is nonetheless possible that feedback effects of
altered frequency-specific input could have selective effects on the projecting pathways to
right A1, including the right SOC and MGN.
5. Conclusions
The goal of the current study was to provide a histological follow-up to Perrino et al.
(2020) [24] by evaluating the consequences of heterozygous and homozygous USH2A mu-
tations on central auditory structures in a transgenic mouse model. We report that Ush2a
HT mice, a putative mouse model for CAPD, exhibited significantly increased right SOC
volumes. Conversely, Ush2a KO mice—a well-accepted mouse model for USH2—exhibited
significantly decreased right SOC volumes, and a shift towards smaller right MGN neurons.
These neuroanatomical abnormalities may contribute to the low-frequency auditory pro-
cessing impairments seen in HT mice, as well as associated language and communication
impairments seen in individuals with pathogenic, heterozygous USH2A variants. Subcorti-
cal anomalies may also contribute to the high-frequency auditory processing impairments
seen in KO mice, corresponding to clinical USH2 symptoms. Importantly, given evidence
of usherin expression in the cochlea but not the brain, our results indicate: (1) an upstream
impact of altered cochlear function on the central auditory system and (2) that the impacts
differ for heterozygous and homozygous Ush2a mutations, commensurate with different
hearing profiles. Future studies will be important in assessing additional central auditory
structures in these mouse models (e.g., inferior colliculus, A1). Taken together, our findings
strongly advocate for early genetic screening as a tool for detecting hearing and auditory
processing disorders that may impact subsequent language development, and add to
evidence from Perrino et al. (2020) [24] that USH2A carriers are not “phenotype-free”.
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